March 2016

New Product - Saxenda

Saxenda (liraglutide (rys)) is a human glucagon-like peptide‑1 (GLP-1) analogue that binds to and activates the GLP‑1 receptor (GLP‑1R). Saxenda is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of ≥ 30 kg/m² (obese) or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (prediabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea. Saxenda is contraindicated with a past history of GLP-1 analogue associated pancreatitis. Saxenda is available as a 3 mL (6 mg/mL) prefilled multidose disposable pen injector in packs of 5’s.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au